Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fipravirimat Dose-Finding Study in Treatment-Naive HIV-1
NCT04493216Phase 2Terminated
- Sponsor
- ViiV Healthcare
- Start
- Nov 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of fipravirimat in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Nov 2020; status: terminated.
02
Drugs
fipravirimat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04493216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493216.